ALSO NOTED: Indian pharmas wring hands over rising rupee; MAP Pharma sets IPO price

> Fearing a loss in export revenues, Indian drug makers want their government to help shield them from recent gains in the value of the rupee. Report

> MAP Pharmaceuticals has set its IPO target at between $14 and $16 per share, planning to sell 5 million shares for a market cap of up to $308 million. Report

> GlaxoSmithKline and Taisho Pharmaceutical will jointly roll out an over-the-counter herpes remedy in Japan as soon as next month. Report

> The FDA gave its blessing to Novo Nordisk's Norditropin drug for use in girls with short stature stemming from Turner Syndrome. Release

And Finally... Resistant bacteria are stubborn little critters especially in intensive care units, and Australian scientists are using pigs to figure out why. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

North Korean hackers were accused of posing as corporate recruiters in a scheme to breach AstraZeneca's computer systems and steal COVID-19 research.

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

McKinsey & Company helped guide Purdue's strategy for years and pitched the idea of rebates to distributors for overdoses, according to the NYT.